CLOSE
MENU
Chordia Therapeutics Inc.
News
News
サブ-ナビゲーション
Company
Science/Pipleline
現在位置:
News
Investor Relations
Career
Contact
Privacy Policy
Term of use
Sitemap
News
Jan 14, 2025
Non-consolidated Financial Results for the Three Months Ended November 30, 2024 [Japanese GAAP]
（432KB）
Jan 10, 2025
Rogocekib for the treatment of Refractory or Relapsed Acute Myologic Lymphoma(AML) has been granted Orphan Drug Designation (ODD) in the US by the FDA
（272KB）
Dec 12, 2024
By FISCO Corporation Notice of Distribution of Our Corporate Research Report
（267KB）
Nov 29, 2024
Corporate Governance Report
（659KB）
Nov 20, 2024
Announcement of International Nonproprietary Name (INN) for CTX-712
（277KB）
Nov 06, 2024
Notice of Convocation of the 7th Annual General Meeting of Shareholders
（942KB）
Oct 28, 2024
Chordia announces the Release of a Transcript of the Earnings Briefing for the Fiscal Year Ended August 2024
（281KB）
Oct 15, 2024
Fiscal year ended August 2024 Financial Results Presentation
（1,465KB）
Oct 11, 2024
Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2024 [Japanese GAAP]
（538KB）
Oct 11, 2024
Chordia to Present Results of Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2024 The 86th Annual Meeting of the Japanese Society of Hematolog
（283KB）
Oct 02, 2024
Chordia was nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2024
（405KB）
Oct 01, 2024
Announcement of Presentation on Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 86th Annual Meeting of the Japanese Society of Hematology
（281KB）
Jul 23, 2024
Chordia wins the Minister of Education, Culture, Sports, Science and Technology Award at the Japan Startup Awards 2024.
（610KB）
Jul 16, 2024
Non-consolidated Financial Results for the Nine Months Ended May 31, 2024 [Japanese GAAP]
（348KB）
Jun 14, 2024
Notice of Listing on the Growth Market of the Tokyo Stock Exchange
（522KB）
Jun 07, 2024
CSO Daisuke Morishita to Speak at the 28th Annua Meeting of Japanese Association for Molecular Target Therapy of Cancer
（280KB）
Apr 17, 2024
Joint presentation about CDK12 at the 76th Annual Meeting of the Japanese Society of Obstetrics and Gynecology
（289KB）
Apr 06, 2024
Chordia Presented at the American Association for Cancer Research Annual Meeting 2024
（304KB）
Mar 14, 2024
Presentation at 3rd regional symposium on Myelodysplastic syndrome
（261KB）
Mar 06, 2024
Presentation of data from our pipeline at the American Association for Cancer Research Annual Meeting 2024
（300KB）
Feb 15, 2024
CSO Daisuke Morishita receives the Minister of State for Science and Technology Policy Award at the 6th Japan Open Innovation Prize
Feb 14, 2024
Chordia CEO to Speak at the Japan Healthcare Venture Summit 2023 Symposium
（269KB）
Jan 29, 2024
Chordia nominated for the 6th Japan Open Innovation Prize
（266KB）
Nov 28, 2023
Published 6th Financial Report
（300KB）
Nov 20, 2023
Chordia Announces Completion of Patient Enrollment in the Phase 1 Study for Solid Tumors and Hematologic Malignancies in Japan
（385KB）
Oct 19, 2023
Chordia named "Financing Deal of the Year." at the Informa Pharma Intelligence Awards Japan 2023
（355KB）
Oct 18, 2023
Chordia named “Judges' Special Award” at Japan Healthcare Venture Summit 2023
（269KB）
Oct 18, 2023
Abstract of the summary presentation of the US Phase 1/2 clinical trial of CTX-712 has been accepted at the 65th ASH
（293KB）
Oct 01, 2023
Yasushi Tanoue appointed Chief Medical Officer (CMO)
（274KB）
Sep 15, 2023
Selected for the latest edition of "100 Amazing Venture Businesses" in 2023
（184KB）
Sep 15, 2023
Nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2023
（267KB）
Jun 01, 2023
Dosing of CLK Inhibitor CTX-712 Starts in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S.
（299KB）
May 17, 2023
Fujitsu, Kyoto University, and Chordia Therapeutics Launch AI Trials to Discover Biomarkers for New Cancer Drugs
（147KB）
Feb 17, 2023
Initiated Phase 1/2 Study of CTX-712, a CLK Inhibitor, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S.
（301KB）
Feb 16, 2023
Receives Development Milestone Payment of CTX-177 (ONO-7018), a MALT1 Inhibitor, According to License Agreement with Ono Pharmaceutical
（238KB）
Dec 12, 2022
Announces Interim Results of CLK Inhibitor CTX-712 and MALT-1 Inhibitor CTX-177 at the 2022 ASH Annual Meeting.
（284KB）
Nov 21, 2022
Published 5th Financial Report
（496KB）
Oct 03, 2022
Chordia Therapeutics Director and Statutory Auditor Appointments
（263KB）
Sep 08, 2022
Chordia Named “Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award” at Academic Startups 2022
（270KB）
Aug 29, 2022
Chordia’s Licensee Ono Pharmaceutical Co., Ltd. Initiated a Phase 1 Study of ONO-7018 (CTX-177), a MALT1 Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.
（281KB）
Jun 07, 2022
Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
（304KB）
Jun 07, 2022
Concludes Basic Agreement on Collaboration with Shionogi Pharma Co., Ltd.
（216KB）
May 19, 2022
Concludes Basic Agreement on Business Tie Up with MEDIPAL HOLDINGS CORPORATION
（232KB）
May 19, 2022
Raises Approximately 4 Billion JPY in Series C Financing, Achieving a Cumulative Total of Approximately 8.2 Billion JPY
（215KB）
May 16, 2022
Featured as a Cover Story in Startup City Magazine’s “Top 10 Japanese Startups 2022”
（2,325KB）
Apr 07, 2022
Nominated as a Finalist of the Informa Pharma Intelligence Awards Japan 2022
（302KB）
Dec 03, 2021
Published 4th financial report
（660KB）
Sep 24, 2021
Assignment of Statutory Auditor
（92KB）
Mar 03, 2021
Interview with CEO Miyake Published in Scrip
Feb 04, 2021
Interview with CSO Morishita Published in AnswersNews
Dec 15, 2020
Notice of License Agreement
（121KB）
Oct 25, 2019
Chordia Therapeutics Announced the Appointment of CMO & CSO
（181KB）
Mar 29, 2019
Chordia Therapeutics Raises Around $27 Million in Series B Financing
（212KB）
Jan 10, 2019
Published Our Article in Forbes JAPAN
Nov 30, 2017
Chordia Therapeutics Raises Around $11 Million in Series A Financing
（562KB）
Nov 22, 2017
Launch of Chordia Therapeutics
（562KB）
VIEW ALL
ページの先頭へ
ページの先頭へ
menu
gnavi-box
.jpg)
